Vaxxas company information, Employees & Contact Information

Vaxxas Secures New U.S. Patent For its Needle-Free Vaccination Manufacturing Technology Business Wire

Vaccination biotech Vaxxas raises $49 million Series D, cuts C-suite amid broader layoffs Startup Daily

Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology BiotechDispatch

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery Business Wire

Vaxxas raises $58.4M for needle-free vaccine delivery tech, announces CEO change Drug Delivery Business

UQ and Vaxxas win prize to advance patch-based mRNA COVID-19 and influenza vaccine UQ News

Vaxxas raises $90m for vaccine tech Manufacturers' Monthly

Vaxxas completes enrolment in Phase I H7N9 bird flu vaccine trial Clinical Trials Arena

SK bioscience and Vaxxas Enter Joint Development Agreement for Needle-Free Patch Delivery of Typhoid Vaccine PR Newswire

Evaluation of the self-administration potential of high-density microarray patches to human skin: A preliminary study Taylor & Francis Online

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access CEPI

Newly Published Data Supports Effective Delivery of DNA-Based Vaccines Using Vaxxas’ High-Density Microarray Patch (HD-MAP) Delivery Technology BioSpace

Vaxxas Appoints Leading Global Vaccine Experts as the Company Advances its Needle-Free Vaccination Technology Towards Late-Stage Clinical Trials Business Wire

Australian company Vaxxas named stage winner of US prize to advance vaccine patches BiotechDispatch

Vaxxas Covid-19 vaccine patch outshines injectable jab in pre-clinical study Clinical Trials Arena

Vaxxas appoints vaccine experts as it prepares for late-stage clinical trials BiotechDispatch

Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines Business Wire

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination Business Wire

Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products Business Wire

Vaxxas Announces Interim Results from Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using Proprietary High-Density Microarray Patch (HD-MAP) Business Wire

Vaxxas Appoints Doug Cubbin as Chief Financial Officer Business Wire

Vaxxas Announces Appointment of Dan Devine as Chief Business Officer and General Counsel Business Wire

Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer Business Wire

Vaxxas CEO and finance boss out amid job losses, capital raising AFR

Vaxxas completes enrollment for largest clinical trial of HD-MAP for vaccine delivery BiotechDispatch

Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response Business Wire

Vaxxas licenses RSV vaccine antigen candidate from the US National Institutes of Health BiotechDispatch

Australia's Vaxxas secures ~A$90 M in funding to commercialise needle-free vaccination delivery technology BioSpectrum Asia

Vaxxas initiates Phase 1 clinical trial of pre-pandemic Avian Influenza A Virus vaccine BiotechDispatch

Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology BiotechDispatch

Australian company Vaxxas receives significant investment from Endpoints Capital BiotechDispatch

Vaxxas – Taking the sting out of vaccinations Manufacturers' Monthly

Vaxxas ramps up its market readiness with $89m in debt and equity funding amid leadership transition Business News Australia

Vaxxas Raises $90 Million To Advance Needle-Free Vaccine Technology SMBtech

Needle-free vaccine innovator Vaxxas banks $34m from OneVentures, UniQuest AFR

Vaxxas opens needle-free vaccine manufacturing site and global HQ in Brisbane BiotechDispatch

Vaxxas: Making needle-free vaccination a reality on a global scale CSIRO

Vaxxas and CEPI advance needle-free mRNA vaccines Manufacturers' Monthly

Future of vaccines needle-free says Vaxxas, but it needs locals to make it happen Australian Broadcasting Corporation

Vaxxas raises $90M to advance needle-free vaccine manufacturing Australian Manufacturing

$7.2 million project using Vaxxas patches for JEV vaccination progresses Australian Manufacturing Forum

Skin in the game: Needle-free COVID vaccine patches a step closer Australian Broadcasting Corporation

Vaxxas appoints Doug Cubbin as its new chief financial officer BiotechDispatch

Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines Stockhead